Mylan history

In 1963, Puskar moved his operations to Princeton, West Virginia, and then moved again two years later, settling in Morgantown, West Virginia.

1965: Vitamins are the first product manufactured under the Milan banner.

In 1972, after a management dispute, Puskar left the company he had founded 11 years earlier, ending the first chapter in the company's history and marking the beginning of a near-disastrous period for the West Virginia pharmaceutical concern.

1973: Going Public To fuel expansion, Mylan goes public.

The board hired Roy McKnight as board chairman, who convinced Puskar to return in 1976.

By 1977, Mylan was once again a profitable company.

Mylan's stock began trading on NASDAQ in 1978.

1982: GPIA and Hatch-Waxman Mike Puskar helps establish the Generic Pharmaceutical Industry Association, GPIA, to give the industry a voice.

The higher dose allowed once per day dosing, which the company and its marketing partner, Lederle, believed would help it compete against Dyazide, which had $210M in sales in 1983.

As these first steps into proprietary drug production were being made, progress was being achieved on other fronts, as Mylan reigned as the leading independent drug manufacturer in the United States, a number one position first achieved in 1985.

1987: Mylan opens a new factory in Caguas, Puerto Rico.

In 1988, after three years of clinical tests, the FDA approved half-strength Maxzide-25, giving the company another powerful revenue-generating engine.

In June 1989, the company acquired a 50 percent stake in Somerset Pharmaceuticals, Incorporated, the same month Somerset secured FDA approval to market a new medication for the treatment of Parkinson's disease called Eldepryl.

1993: New CEO Mike Puskar becomes chairman and CEO.

To give the company the manufacturing might to correspond to its growing presence, a third generic drug production facility was opened in Cidra, Puerto Rico, in late 1994, further bolstering the company’s manufacturing capabilities in one of the havens of pharmaceutical production in the world.

Sales recorded their most prolific leap during the first half of the decade in 1995, catapulting from $252 million to $396 million, from which the company registered an astounding $121 million in net earnings, nearly twice the total earned the previous year.

The company’s dedication to maintaining its position in the pharmaceutical industry was demonstrated in late 1996 when it opened a 150,000-square-foot research facility with bed space for 104 research subjects and two large laboratories.

Actelion profile and corporate video Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.

The next step in this effort came in October 1998, when Mylan purchased Penederm Inc., maker of branded dermatological creams and products, for about $200 million.

Penederm was transformed into Bertek's Dermatology Division in August 1999.

2000: Mylan agrees to settle all suits brought in connection with the anticompetitive charges, taking a $147 million charge to cover the cost of the settlements.

Revenues for 2001 reached a record $846.7 million.

In between, in September 2002, the company appointed a new CEO, Robert J. Coury.

In September 2003 the attorney general of Massachusetts filed suit against Mylan and 12 other pharmaceutical companies, accusing them of over-charging Medicaid plans as part of the practices they used to price generic drugs.

Afterwards, Icahn offered to buy Mylan for $5.4B and nominated a slate of board members to change the direction of Mylan; he won three seats in May 2005.

2006: Setting New Standards in Healthcare Executive Heather Bresch testifies before the United States Senate’s Special Committee on Ageing regarding issues that put billions of dollars of consumer healthcare savings at risk.

2009: Global Leadership Mike Puskar retires and Robert J. Coury is named chairman of the board.

2010: Bioniche Pharma Our acquisition of Bioniche Pharma expands our injectable portfolio with products for use in orthopaedics, rheumatology, urology and dermatology.

2011: Our First 50 Years Mylan celebrates 50 years of unconventional success.

The company had earlier quality control issues involving the FDA. The lawsuits were dropped in 2012 without any damages paid by the Post-Gazette, which stated "The Post-Gazette did not find and did not intend to report that Mylan had manufactured or distributed any defective drugs.

2013: New Global Centre Operations begin at our new Robert J. Coury Global Centre in Pittsburgh, Pennsylvania, a 280,000-square-foot, five-story innovative workspace.

In April 2015, the company attempted a hostile takeover of Perrigo, offering to buy $26 billion in shares directly from shareholders.

In February 2016, the company announced it would acquire Meda AB for $9.9 billion.

In October 2017, the company announced the launch of the first FDA-approved generic of Teva’s long-acting Copaxone.

In May 2018, the company announced a collaboration with West Virginia University to expose children across West Virginia to STEM educational initiatives.

In January 2019, the FDA announced its approval of the company's Wixela Inhub, the first approved generic version of GlaxoSmithKline's Advair Diskus.